Pharma Share Buybacks Could Draw Policymakers’ Scrutiny, Professor Warns
This article was originally published in The Pink Sheet Daily
Executive Summary
In current economic climate, trade-offs between buybacks and R&D investment could get a closer look, University of Massachusetts prof says at economic conference.
You may also be interested in...
Can't Say No: Pharma's Addiction to Shareholder Payouts
Having created a shareholder addiction to cash payments, companies are now going to have to make the unpleasant choice between pleasing investors in the short term and building their businesses over the next decade. IN VIVO examines pipeline confidence, patent expirations, and cash flow woes to make some forecasts about the industry's financial health, as well as looking inside the strategies that Big Pharma is currently pursuing.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.